AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
1min snip
The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
ACQ2 by Acquired
Dual Mechanisms for Treating Diabetes and Obesity
The speaker was inspired by a colleague's work in a pharma setting to develop a drug that can target both type two diabetes and obesity simultaneously. The drug, Jilpewon, is designed to increase insulin levels and lower another hormone called glucogram to treat diabetes. It also includes a safety switch to prevent hypoglycemia. Additionally, Jilpewon targets weight loss by acting on the brain, the main organ for regulating eating habits, with some effects on the peripheral nervous system.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode